Kidney Week 2025 Annual Meeting-Opening Plenary: ASN President's Address, State-of-the-Art Lecture, Featured High-Impact Clinical Trials

Video Transcription

Video Summary

The transcript highlights a turning point in nephrology showcased at ASN Kidney Week 2025. ASN, a global community of 22,000 professionals, emphasizes rapid advances in early diagnosis, biomarkers, AI, transplantation, regenerative medicine, and new therapies that slow CKD progression beyond dialysis—paired with a strong push for equity and global access.<br /><br />ASN President Dr. Prabir Roy-Chowdhury reflects on the long “therapeutic stagnation” after ACE inhibitors/ARBs, contrasting it with today’s momentum: numerous emerging therapies across kidney disease types, value-based care models, and a growing innovation “substrate.” He cites the NIH Kidney Precision Medicine Project (linking biopsies and multi-omics to targets/biomarkers) and the ASN–FDA Kidney Health Initiative, including work validating proteinuria reduction as a surrogate endpoint in IgA nephropathy, accelerating trials and approvals. He stresses disparities, global challenges (including CKD of unknown origin), workforce needs, and ASN investments in bridge funding and workforce training.<br /><br />Provost/nephrology trialist Dr. Vlado Perkovic argues kidney disease can move toward “remission” and eventually cure, pointing to transformative evidence for SGLT2 inhibitors, finerenone, and semaglutide in diabetic kidney disease and the potential power of combination “four-pillar” therapy. For IgA nephropathy, he describes an explosion of trials and promising B-cell–targeted therapies that may stabilize eGFR.<br /><br />Late-breaking trials include FIND-1: finerenone in CKD with type 1 diabetes reduced albuminuria ~25% vs placebo with manageable hyperkalemia. The ARGEN3 Phase III interim results show atacicept (BAFF/APRIL blockade) reduced proteinuria ~42%, improved key biomarkers, and had favorable safety, with longer-term eGFR outcomes pending. Overall, speakers frame 2025 as an inflection point where implementation, collaboration, and equity will determine whether innovation translates into fewer patients reaching kidney failure.

Asset Subtitle

Presentation(s):

ASN President's Address - Prabir Roy-Chaudhury
State-of-the-Art Lecture "Yes We Can...Cure Kidney Diseases" - Vlado Perkovic
Finerenone in CKD and Type 1 Diabetes - Hiddo Heerspink
ORIGIN 3: A Phase 3 Trial of Atacicept in IgAN - Richard Lafayette
Clinical Trials Expert Panel - Julie Ingelfinger, Alan Kliger, Vlado Perkovic

Note: Continuing education credits are not being offered for this session.

Meta Tag

Date 11/6/2025

Pathway 1 Other

Session ID 528197

Keywords

ASN Kidney Week 2025

nephrology innovation

chronic kidney disease (CKD) progression

early diagnosis and biomarkers

artificial intelligence in nephrology

kidney transplantation and regenerative medicine

health equity and global access

NIH Kidney Precision Medicine Project

multi-omics kidney biopsy targets

ASN–FDA Kidney Health Initiative

proteinuria surrogate endpoint (IgA nephropathy)

SGLT2 inhibitors finerenone semaglutide four-pillar therapy

atacicept ARGEN3 and FIND-1 late-breaking trials